BMS leans on new long-term Opdivo data in crowded kidney cancer field

18th February 2020 Uncategorised 0

Bristol-Myers Squibb’s Opdivo-Yervoy combo is competing in an increasingly crowded space when it comes to previously untreated kidney cancer. But the company is leaning on long-term data to help set its regimen apart. More than half of patients treated with the pairing were alive at the 42-month mark, compared with 39% of those taking Pfizer’s Sutent, the New Jersey drugmaker showed over the weekend.

More: BMS leans on new long-term Opdivo data in crowded kidney cancer field
Source: fierce